Publication | Closed Access

Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor

First Targeted TherapyBreast OncologyMedicinePharmacologyImmune Checkpoint InhibitorBreast CancerPharmacotherapyTriple-negative Breast CancerAnti-cancer AgentCancer TreatmentOncologyCell BiologyDrug Discovery